The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Described herein are molecular glue degrader compounds that bind to both a target protein and a RING E3 Ubiquitin Ligase, as well as related compositions and methods of use, e.g., for degradation of the target protein and/or the treatment of a disease, disorder, or condition.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations. Collection and preservation of biological tissue, blood and
cells; Medical diagnostic services; medical treatment
services; provision of information and data for diagnosis
and medical treatment.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations. Collection and preservation of biological tissue, blood and
cells; Medical diagnostic services; medical treatment
services; provision of information and data for diagnosis
and medical treatment.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations. Collection and preservation of biological tissue, blood and
cells; Medical diagnostic services; medical treatment
services; provision of information and data for diagnosis
and medical treatment.
123455, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.
C07D 487/12 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains three hetero rings
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 35/02 - Antineoplastic agents specific for leukemia
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the prevention and treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for the prevention and treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; anti-inflammatories; pharmaceutical preparations for the prevention and treatment of disorders of the respiratory system; pharmaceutical preparations for the prevention and treatment of disorders of the musculo-skeletal system, namely, connective tissue disease, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the prevention and treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for use in dermatology, namely, for the prevention and treatment of psoriasis, urticaria, hidradenitis suppurativa, dermatitis, skin pigmentation diseases, sexually transmitted diseases; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in hematology, namely for the treatment of blood disorders; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for prevention and treatment of ocular disorders and diseases; anti-infectives, anti-bacterials, antivirals, anti-biotics, systemic and topical antifungals.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations.
13.
DUAL-ACTING PHARMACEUTICAL COMPOSITIONS BASED ON SUPERSTRUCTURES OF ANGIOTENSIN RECEPTOR ANTAGONIST/BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR
Solid oral dosage forms, especially tablets, of a pharmaceutical composition comprising a supramolecular complex can be formed from a direct compression process or a compaction process such as roller compaction. Such solid oral dosage forms feature an immediate release profile that allows for fast release of the therapeutic agent. A particularly useful supramolecular complex is trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate]hemipentahydrate.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
14.
METHODS OF TREATING METABOLIC DISORDERS WITH FGF21 VARIANTS
Provided herein are methods of treating, preventing, and managing metabolic or cardiovascular disorders and methods of reducing cardiovascular risk with FGF21 protein variants, including Fc-FGF21 variant fusion proteins.
The present disclosure provides methods for treating an estrogen receptor mediated disease, disorder, or condition in a subject comprising administering to the subject a composition comprising Compound 1 or a pharmaceutically acceptable salt thereof in combination with ribociclib, or a pharmaceutically acceptable salt thereof.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The present disclosure provides methods for treating an estrogen receptor mediated disease, disorder, or condition in a subject comprising administering to the subject a composition comprising Compound (1) or a pharmaceutically acceptable salt thereof in combination with alpelisib, or a pharmaceutically acceptable salt thereof.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
19.
SYNTHESIS METHODS AND INTERMEDIATES FOR THE PRODUCTION OF REMIBRUTINIB
This invention relates to novel processes for synthesizing N-(3-(6-Amino-5-(2-(N- methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide and to intermediates which are used in such processes.
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07C 233/59 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and gene therapy products in the
nature of injectable biologic preparations for genetic,
neurological, motor neuron, or neuromuscular diseases,
disorders and conditions; pharmaceutical preparations and
gene therapy products in the nature of biological
preparations containing genetic materials for treating
spinal muscular atrophy, loss of motor neurons, muscle
degeneration, muscle weakness, and paralysis; gene therapy
preparations in the nature of biological preparations
containing genetic materials for sustained survival motor
neuron protein expression.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and gene therapy products in the
nature of injectable biologic preparations for genetic,
neurological, motor neuron, or neuromuscular diseases,
disorders and conditions; pharmaceutical preparations and
gene therapy products in the nature of biological
preparations containing genetic materials for treating
spinal muscular atrophy, loss of motor neurons, muscle
degeneration, muscle weakness, and paralysis; gene therapy
preparations in the nature of biological preparations
containing genetic materials for sustained survival motor
neuron protein expression.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and gene therapy products in the
nature of injectable biologic preparations for genetic,
neurological, motor neuron, or neuromuscular diseases,
disorders and conditions; pharmaceutical preparations and
gene therapy products in the nature of biological
preparations containing genetic materials for treating
spinal muscular atrophy, loss of motor neurons, muscle
degeneration, muscle weakness, and paralysis; gene therapy
preparations in the nature of biological preparations
containing genetic materials for sustained survival motor
neuron protein expression.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations. Computer software; Computer application (software); computer
software for data processing; electronic apparatus,
electronic equipment, software, programs and systems for the
capture, collection, conversion, analysis, communication,
processing, reception, recording, storage and/or
transmission of data, images and information; mechanisms for
data processing equipment, computers; data sets, recorded or
downloadable; electronic apparatus, electronic equipment,
software, programs and systems for the conversion, analysis,
processing, storage and transmission of artificial
intelligence; artificial intelligence and machine learning
software for statistical analysis, consultancy and
reporting; software for analytics in the fields of public
health, healthcare, pharmaceuticals, biotechnology,
biomedical research and development, clinical trials;
computer software for database integration; computer
software for creating searchable databases of information
and data; computer software featuring electronic computer
databases of medical research data, clinical trial data,
patient information and medical industry stakeholder
information; computer software for accessing data and
information related to patient medical information, medical
research data and clinical trial data and for controlling
and managing data and information related to medical
research data, patient medical information and clinical
trial data; computer software platforms for integrating
clinical and non-clinical patient and medical data; computer
software to enable sharing of data and comments among users;
data communication apparatus for transmitting data and
information to databases; downloadable software in the
nature of mobile applications; all the aforesaid goods to be
used in the medical and healthcare fields. Medical apparatus and instruments.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and gene therapy products in the
nature of injectable biologic preparations for genetic,
neurological, motor neuron, or neuromuscular diseases,
disorders and conditions; pharmaceutical preparations and
gene therapy products in the nature of biological
preparations containing genetic materials for treating
spinal muscular atrophy, loss of motor neurons, muscle
degeneration, muscle weakness, and paralysis; gene therapy
preparations in the nature of biological preparations
containing genetic materials for sustained survival motor
neuron protein expression.
This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods, and therapeutic uses thereof for treating autoimmune diseases or disorders.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
28.
USE OF MGLUR5 ANTAGONISTS FOR TREATING GAMBLING DISORDER
The present invention relates to the use of mavoglurant in the treatment of gambling disorder. The present invention also relates to the use of mavoglurant in the treatment of gaming disorder.
It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.
The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
This invention relates to methods employing IL-1 beta-ligand/IL-1 receptor disrupting compounds, such as IL-1 beta antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of auto-inflammatory syndromes in mammals, particularly humans.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The invention provides methods for manufacturing optimized CAR T cell therapies and uses thereof. Specifically, the invention provides parameters that can be measured, e.g., evaluated, to manufacture CAR T cell therapies with optimized properties. The invention further provides methods of use in connection with said optimized CAR T cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à savoir les infections du système nerveux central, les maladies du cerveau, les troubles du mouvement du système nerveux central, les troubles de la motilité oculaire, les maladies de la moelle épinière; préparations pharmaceutiques pour la prévention et le traitement de maladies immunologiques, à savoir des maladies auto-immunes, des syndromes de déficit immunitaire; préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques pour la prévention et le traitement du diabète; préparations pharmaceutiques pour la prévention et le traitement des troubles métaboliques, à savoir le diabète, l'obésité, l'hyperlipidémie, la résistance à l'insuline, le syndrome métabolique; anti-inflammatoires; préparations pharmaceutiques pour la prévention et le traitement des troubles du système respiratoire; préparations pharmaceutiques pour la prévention et le traitement des troubles du système musculo- squelettique, à savoir les maladies du tissu conjonctif, les maladies des os, les maladies de la colonne vertébrale, les maux de dos, les fractures, les entorses, les blessures du cartilage; préparations pharmaceutiques pour la prévention et le traitement des maladies génito-urinaires, à savoir les maladies urologiques, l'infertilité, les maladies sexuellement transmissibles, les inflammations pelviennes; préparations pharmaceutiques pour utilisation en dermatologie, à savoir pour la prévention et le traitement du psoriasis, de l'urticaire, de l'hidradénite suppurée, de la dermatite, des maladies affectant la pigmentation de la peau, des maladies sexuellement transmissibles; préparations pharmaceutiques utilisées en oncologie; préparations pharmaceutiques utilisées en hématologie, à savoir pour le traitement des troubles sanguins;préparations pharmaceutiques utilisée pour la transplantation de tissus et d'organes; préparations pharmaceutiques utilisées en ophtalmologie; préparations pharmaceutiques utilisées en gastroentérologie; préparations pharmaceutiques pour la prévention et le traitement des troubles et des maladies oculaires; anti-infectieux, antibactériens, antiviraux, antibiotiques, antifongiques systémiques et topiques.
41 - Education, entertainment, sporting and cultural services
Goods & Services
Ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products; cannulas and needles for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; adhesive pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; magnetic pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space Training services in the field of ophthalmic surgical procedures; training services in the field of ophthalmic surgical equipment and the use and operation thereof; educational services, namely, conducting in-person classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, conducting online classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing in-person instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing online instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive in-person training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive online training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment
41 - Education, entertainment, sporting and cultural services
Goods & Services
Ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products; cannulas and needles for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; adhesive pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; magnetic pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space. Training services in the field of ophthalmic surgical procedures; training services in the field of ophthalmic surgical equipment and the use and operation thereof; educational services, namely, conducting in-person classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, conducting online classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing in-person instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing online instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive in-person training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive online training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment.
41 - Education, entertainment, sporting and cultural services
Goods & Services
Ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products; cannulas and needles for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; adhesive pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; magnetic pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space Training services in the field of ophthalmic surgical procedures; training services in the field of ophthalmic surgical equipment and the use and operation thereof; educational services, namely, conducting in-person classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, conducting online classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing in-person instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing online instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive in-person training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive online training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment
40.
NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES
The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:
The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:
wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 38/095 - Oxytocins; Vasopressins; Related peptides
A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I):
The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I):
The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I):
wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
Inventor
Brannetti, Barbara
Brogdon, Jennifer
Engels, Boris
Granda, Brian
Huang, Lu
Lei, Ming
Li, Na
Zhang, Jimin
Guimaraes, Carla
Gill, Saar
Ruella, Marco
Young, Regina M.
Abstract
The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
The present disclosure provides methods for measuring activity of cellular retinaldehyde-binding protein (CRALBP) or potency of a composition comprising an AAV vector comprising a CRALBP coding sequence for expressing a CRALBP protein. Also provided are kits for use in measuring activity of CRALBP.
The instant disclosure relates to compositions comprising SARS-CoV-2 binding molecules and methods of use thereof. Provided herein are dosing regimens for administration of SARS-CoV-2 binding molecules, including the DARPin® protein ensovibep.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and medical preparations; sanitary preparations for medical purposes; pharmaceutical preparations for pain relief; plant based pharmaceutical preparations; plant extracts for pharmaceutical purposes; topical analgesics; topical anti-inflammatories; adhesive patches for medical purposes; adhesive patches incorporating pharmaceutical preparations; dietetic food and substances adapted for medical or veterinary use; dietary supplements for humans.
The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/443 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à savoir les infections du système nerveux central, les maladies du cerveau, les troubles du mouvement du système nerveux central, les troubles de la motilité oculaire, les maladies de la moelle épinière; préparations pharmaceutiques pour la prévention et le traitement de maladies immunologiques, à savoir des maladies auto-immunes, des syndromes de déficit immunitaire; préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques pour la prévention et le traitement du diabète; préparations pharmaceutiques pour la prévention et le traitement des troubles métaboliques, à savoir le diabète, l'obésité, l'hyperlipidémie, la résistance à l'insuline, le syndrome métabolique; anti-inflammatoires; préparations pharmaceutiques pour la prévention et le traitement des troubles du système respiratoire; préparations pharmaceutiques pour la prévention et le traitement des troubles du système musculo-squelettique, à savoir les maladies du tissu conjonctif, les maladies des os, les maladies de la colonne vertébrale, les maux de dos, les fractures, les entorses, les blessures du cartilage; préparations pharmaceutiques pour la prévention et le traitement des maladies génito-urinaires, à savoir les maladies urologiques, l'infertilité, les maladies sexuellement transmissibles, les inflammations pelviennes; préparations pharmaceutiques pour utilisation en dermatologie, à savoir pour la prévention et le traitement du psoriasis, de l'urticaire, de l'hidradénite suppurée, de la dermatite, des maladies affectant la pigmentation de la peau, des maladies sexuellement transmissibles; préparations pharmaceutiques utilisées en oncologie; préparations pharmaceutiques utilisées en hématologie, à savoir pour le traitement des troubles sanguins; préparations pharmaceutiques utilisée pour la transplantation de tissus et d'organes; préparations pharmaceutiques utilisées en ophtalmologie; préparations pharmaceutiques utilisées en gastroentérologie; préparations pharmaceutiques pour la prévention et le traitement des troubles et des maladies oculaires; anti-infectieux, antibactériens, antiviraux, antibiotiques, antifongiques systémiques et topiques.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the prevention and treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for the prevention and treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; anti-inflammatories; pharmaceutical preparations for the prevention and treatment of disorders of the respiratory system; pharmaceutical preparations for the prevention and treatment of disorders of the musculo-skeletal system, namely, connective tissue disease, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the prevention and treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for use in dermatology, namely, for the prevention and treatment of psoriasis, urticaria, hidradenitis suppurativa, dermatitis, skin pigmentation diseases, sexually transmitted diseases; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in hematology, namely for the treatment of blood disorders; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for prevention and treatment of ocular disorders and diseases; anti-infectives, anti-bacterials, antivirals, anti-biotics, systemic and topical antifungals.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à savoir les infections du système nerveux central, les maladies du cerveau, les troubles du mouvement du système nerveux central, les troubles de la motilité oculaire, les maladies de la moelle épinière; préparations pharmaceutiques pour la prévention et le traitement de maladies immunologiques, à savoir des maladies auto-immunes, des syndromes de déficit immunitaire; préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques pour la prévention et le traitement du diabète; préparations pharmaceutiques pour la prévention et le traitement des troubles métaboliques, à savoir le diabète, l'obésité, l'hyperlipidémie, la résistance à l'insuline, le syndrome métabolique; anti-inflammatoires; préparations pharmaceutiques pour la prévention et le traitement des troubles du système respiratoire; préparations pharmaceutiques pour la prévention et le traitement des troubles du système musculo-squelettique, à savoir les maladies du tissu conjonctif, les maladies des os, les maladies de la colonne vertébrale, les maux de dos, les fractures, les entorses, les blessures du cartilage; préparations pharmaceutiques pour la prévention et le traitement des maladies génito-urinaires, à savoir les maladies urologiques, l'infertilité, les maladies sexuellement transmissibles, les inflammations pelviennes; préparations pharmaceutiques pour utilisation en dermatologie, à savoir pour la prévention et le traitement du psoriasis, de l'urticaire, de l'hidradénite suppurée, de la dermatite, des maladies affectant la pigmentation de la peau, des maladies sexuellement transmissibles; préparations pharmaceutiques utilisées en oncologie; préparations pharmaceutiques utilisées en hématologie, à savoir pour le traitement des troubles sanguins; préparations pharmaceutiques utilisée pour la transplantation de tissus et d'organes; préparations pharmaceutiques utilisées en ophtalmologie; préparations pharmaceutiques utilisées en gastroentérologie; préparations pharmaceutiques pour la prévention et le traitement des troubles et des maladies oculaires; anti-infectieux, antibactériens, antiviraux, antibiotiques, antifongiques systémiques et topiques.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à savoir les infections du système nerveux central, les maladies du cerveau, les troubles du mouvement du système nerveux central, les troubles de la motilité oculaire, les maladies de la moelle épinière; préparations pharmaceutiques pour la prévention et le traitement de maladies immunologiques, à savoir des maladies auto-immunes, des syndromes de déficit immunitaire; préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques pour la prévention et le traitement du diabète; préparations pharmaceutiques pour la prévention et le traitement des troubles métaboliques, à savoir le diabète, l'obésité, l'hyperlipidémie, la résistance à l'insuline, le syndrome métabolique; anti-inflammatoires; préparations pharmaceutiques pour la prévention et le traitement des troubles du système respiratoire; préparations pharmaceutiques pour la prévention et le traitement des troubles du système musculo-squelettique, à savoir les maladies du tissu conjonctif, les maladies des os, les maladies de la colonne vertébrale, les maux de dos, les fractures, les entorses, les blessures du cartilage; préparations pharmaceutiques pour la prévention et le traitement des maladies génito-urinaires, à savoir les maladies urologiques, l'infertilité, les maladies sexuellement transmissibles, les inflammations pelviennes; préparations pharmaceutiques pour utilisation en dermatologie, à savoir pour la prévention et le traitement du psoriasis, de l'urticaire, de l'hidradénite suppurée, de la dermatite, des maladies affectant la pigmentation de la peau, des maladies sexuellement transmissibles; préparations pharmaceutiques utilisées en oncologie; préparations pharmaceutiques utilisées en hématologie, à savoir pour le traitement des troubles sanguins; préparations pharmaceutiques utilisée pour la transplantation de tissus et d'organes; préparations pharmaceutiques utilisées en ophtalmologie; préparations pharmaceutiques utilisées en gastroentérologie; préparations pharmaceutiques pour la prévention et le traitement des troubles et des maladies oculaires; anti-infectieux, antibactériens, antiviraux, antibiotiques, antifongiques systémiques et topiques.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and gene therapy products in the nature of injectable biologic preparations for genetic, neurological, motor neuron, or neuromuscular diseases, disorders and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials for treating spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy preparation in the nature of biological preparations containing genetic materials for sustained survival motor neuron protein expression
The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.
The present disclosure relates to a compound of Formula (I): (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein Ring A, and R1 through R4 are as defined herein, and methods of making and using the same.
The present disclosure relates to a compound of Formula (I): (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein Ring A, and R1 through R4 are as defined herein, and methods of making and using the same.
The invention relates to the mavoglurant, or a pharmaceutically acceptable salt thereof: in the treatment of substance use disorder, wherein the substance is an amphetamine-type stimulant; in a treatment in the reduction of substance use by a substance use disorder patient, wherein the substance is an amphetamine-type stimulant; in a treatment to prevent relapse into substance use by a substance use disorder patient, wherein the substance is an amphetamine-type stimulant; in a treatment to promote substance abstinence by a substance use disorder patient, wherein the substance is an amphetamine-type stimulant; in the treatment of the symptoms of depression or anxiety associated with substance use disorder, wherein the substance is an amphetamine-type stimulant.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
The present disclosure relates to use of reversal agents which specifically bind to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies or antigen binding fragments thereof, and reverse one or more effects of the anti-NPR1 antibody or antigen binding fragments thereof (e.g., hypotensive effects).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure relates to αvβ3 and/or αvβ5 integrins antagonist radiopharmaceuticals and their use in a theragnostic approach for selection and therapy of human subjects with tumors overexpressing αvβ3 and/or αvβ5 integrins. In particular, the present disclosure relates to a pharmaceutical composition of αv 177Lu radiolabeled αvβ3 and/or αvβ5 integrins antagonist, for use in treating tumors overexpressing αvβ3 and/or αvβ5 integrins in a human subject eligible for said treatment, wherein said subject has been selected for the treatment by PET/CT or PET/MRI or SPECT/CT or SPECT/MRI imaging with the same αvβ3 and/or αvβ5 integrins antagonist but with 68-Ga as radiometal for use as imaging agent.
The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition comprising N (3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4- yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, or a pharmaceutically acceptable salt thereof. The present invention also provides a process for preparing said pharmaceutical compositions for oral administration and methods of treatment with said pharmaceutical compositions.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour le diagnostic et le traitement de maladies et de troubles oncologiques; préparations pharmaceutiques destinées à accroître l'efficacité d'autres produits pharmaceutiques dans le traitement de maladies oncologiques; agents d'administration de médicaments consistant en des composés qui facilitent l'administration d'une large gamme de produits pharmaceutiques pour traiter le cancer.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à savoir les infections du système nerveux central, les maladies du cerveau, les troubles du mouvement du système nerveux central, les troubles de la motilité oculaire, les maladies de la moelle épinière; préparations pharmaceutiques pour la prévention et le traitement de maladies immunologiques, à savoir des maladies auto-immunes, des syndromes de déficit immunitaire; préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques pour la prévention et le traitement du diabète; préparations pharmaceutiques pour la prévention et le traitement des troubles métaboliques, à savoir le diabète, l'obésité, l'hyperlipidémie, la résistance à l'insuline, le syndrome métabolique; anti-inflammatoires; préparations pharmaceutiques pour la prévention et le traitement des troubles du système respiratoire; préparations pharmaceutiques pour la prévention et le traitement des troubles du système musculo-squelettique, à savoir les maladies du tissu conjonctif, les maladies des os, les maladies de la colonne vertébrale, les maux de dos, les fractures, les entorses, les blessures du cartilage; préparations pharmaceutiques pour la prévention et le traitement des maladies génito-urinaires, à savoir les maladies urologiques, l'infertilité, les maladies sexuellement transmissibles, les inflammations pelviennes; préparations pharmaceutiques pour utilisation en dermatologie, à savoir pour la prévention et le traitement du psoriasis, de l'urticaire, de l'hidradénite suppurée, de la dermatite, des maladies affectant la pigmentation de la peau, des maladies sexuellement transmissibles; préparations pharmaceutiques utilisées en oncologie;préparations pharmaceutiques utilisées en hématologie, à savoir pour le traitement des troubles sanguins; préparations pharmaceutiques utilisée pour la transplantation de tissus et d'organes; préparations pharmaceutiques utilisées en ophtalmologie; préparations pharmaceutiques utilisées en gastroentérologie; préparations pharmaceutiques pour la prévention et le traitement des troubles et des maladies oculaires; anti-infectieux, antibactériens, antiviraux, antibiotiques, antifongiques systémiques et topiques.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides
Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to canakinumab for use in reducing the risk of or preventing recurrent cardiovascular (CV) events in a patient with elevated hsCRP that has suffered myocardial infarction (MI).
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulins; Fragments thereof
The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
The invention relates to a dosage regimen of Compound (I), or a pharmaceutically acceptable salt thereof, for the treatment of diseases or disorders mediated by negative allosteric modulation or inhibition of NR2B-NMDA receptor including, but not limited to, major depressive disorder, treatment resistant depression and suicidality. The invention also relates to the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the treatment of major depressive disorder in patients with suicidal ideation with intent.
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;
wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
41 - Education, entertainment, sporting and cultural services
Goods & Services
Ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products; cannulas and needles for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; adhesive pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; magnetic pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space Training services in the field of ophthalmic surgical procedures; training services in the field of ophthalmic surgical equipment and the use and operation thereof; educational services, namely, conducting in-person classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, conducting online classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing in-person instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing online instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive in-person training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive online training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases; pharmaceuticals for the prevention and treatment of heart rhythm disorders; pharmaceuticals for the prevention and treatment of immune system related diseases and disorders, pharmaceutical preparations for the prevention and treatment of kidney diseases; preparations for the immune system; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à savoir les infections du système nerveux central, les maladies du cerveau, les troubles du mouvement du système nerveux central, les troubles de la motilité oculaire, les maladies de la moelle épinière; préparations pharmaceutiques pour la prévention et le traitement de maladies immunologiques, à savoir des maladies auto-immunes, des syndromes de déficit immunitaire; préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques pour la prévention et le traitement du diabète; préparations pharmaceutiques pour la prévention et le traitement des troubles métaboliques, à savoir le diabète, l'obésité, l'hyperlipidémie, la résistance à l'insuline, le syndrome métabolique; anti-inflammatoires; préparations pharmaceutiques pour la prévention et le traitement des troubles du système respiratoire; préparations pharmaceutiques pour la prévention et le traitement des troubles du système musculo-squelettique, à savoir les maladies du tissu conjonctif, les maladies des os, les maladies de la colonne vertébrale, les maux de dos, les fractures, les entorses, les blessures du cartilage; préparations pharmaceutiques pour la prévention et le traitement des maladies génito-urinaires, à savoir les maladies urologiques, l'infertilité, les maladies sexuellement transmissibles, les inflammations pelviennes; préparations pharmaceutiques pour utilisation en dermatologie, à savoir pour la prévention et le traitement du psoriasis, de l'urticaire, de l'hidradénite suppurée, de la dermatite, des maladies affectant la pigmentation dela peau, des maladies sexuellement transmissibles; préparations pharmaceutiques utilisées en oncologie; préparations pharmaceutiques utilisées en hématologie, à savoir pour le traitement des troubles sanguins; préparations pharmaceutiques utilisées pour la transplantation de tissus et d'organes; préparations pharmaceutiques utilisées en ophtalmologie; préparations pharmaceutiques utilisées en gastroentérologie; préparations pharmaceutiques pour la prévention et le traitement des troubles et des maladies oculaires; anti-infectieux, antibactériens, antiviraux, antibiotiques, antifongiques systémiques et topiques. (1) Prélèvement et conservation de tissus biologiques, de sang et de cellules; services de diagnostic médical; services de traitement médical; mise à disposition d'information et de données pour le diagnostic et le traitement médical.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à savoir les infections du système nerveux central, les maladies du cerveau, les troubles du mouvement du système nerveux central, les troubles de la motilité oculaire, les maladies de la moelle épinière; préparations pharmaceutiques pour la prévention et le traitement de maladies immunologiques, à savoir des maladies auto-immunes, des syndromes de déficit immunitaire; préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques pour la prévention et le traitement du diabète; préparations pharmaceutiques pour la prévention et le traitement des troubles métaboliques, à savoir le diabète, l'obésité, l'hyperlipidémie, la résistance à l'insuline, le syndrome métabolique; anti-inflammatoires; préparations pharmaceutiques pour la prévention et le traitement des troubles du système respiratoire; préparations pharmaceutiques pour la prévention et le traitement des troubles du système musculo-squelettique, à savoir les maladies du tissu conjonctif, les maladies des os, les maladies de la colonne vertébrale, les maux de dos, les fractures, les entorses, les blessures du cartilage; préparations pharmaceutiques pour la prévention et le traitement des maladies génito-urinaires, à savoir les maladies urologiques, l'infertilité, les maladies sexuellement transmissibles, les inflammations pelviennes; préparations pharmaceutiques pour utilisation en dermatologie, à savoir pour la prévention et le traitement du psoriasis, de l'urticaire, de l'hidradénite suppurée, de la dermatite, des maladies affectant la pigmentation de la peau, des maladies sexuellement transmissibles; préparations pharmaceutiques utilisées en oncologie; préparations pharmaceutiques utilisées en hématologie, à savoir pour le traitement des troubles sanguins; préparations pharmaceutiques utilisées pour la transplantation de tissus et d'organes; préparations pharmaceutiques utilisées en ophtalmologie; préparations pharmaceutiques utilisées en gastroentérologie; préparations pharmaceutiques pour la prévention et le traitement des troubles et des maladies oculaires; anti-infectieux, antibactériens, antiviraux, antibiotiques, antifongiques systémiques et topiques.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour la prévention et le traitement du système nerveux central, à savoir les infections du système nerveux central, les maladies du cerveau, les troubles du mouvement du système nerveux central, les troubles de la motilité oculaire, les maladies de la moelle épinière; préparations pharmaceutiques pour la prévention et le traitement de maladies immunologiques, à savoir des maladies auto-immunes, des syndromes de déficit immunitaire; préparations pharmaceutiques pour la prévention et le traitement des maladies cardiovasculaires; préparations pharmaceutiques pour la prévention et le traitement du diabète; préparations pharmaceutiques pour la prévention et le traitement des troubles métaboliques, à savoir le diabète, l'obésité, l'hyperlipidémie, la résistance à l'insuline, le syndrome métabolique; anti-inflammatoires; préparations pharmaceutiques pour la prévention et le traitement des troubles du système respiratoire; préparations pharmaceutiques pour la prévention et le traitement des troubles du système musculo-squelettique, à savoir les maladies du tissu conjonctif, les maladies des os, les maladies de la colonne vertébrale, les maux de dos, les fractures, les entorses, les blessures du cartilage; préparations pharmaceutiques pour la prévention et le traitement des maladies génito-urinaires, à savoir les maladies urologiques, l'infertilité, les maladies sexuellement transmissibles, les inflammations pelviennes; préparations pharmaceutiques pour utilisation en dermatologie, à savoir pour la prévention et le traitement du psoriasis, de l'urticaire, de l'hidradénite suppurée, de la dermatite, des maladies affectant la pigmentation de la peau, des maladies sexuellement transmissibles; préparations pharmaceutiques utilisées en oncologie; préparations pharmaceutiques utilisées en hématologie, à savoir pour le traitement des troubles sanguins; préparations pharmaceutiques utilisées pour la transplantation de tissus et d'organes; préparations pharmaceutiques utilisées en ophtalmologie; préparations pharmaceutiques utilisées en gastroentérologie; préparations pharmaceutiques pour la prévention et le traitement des troubles et des maladies oculaires; anti-infectieux, antibactériens, antiviraux, antibiotiques, antifongiques systémiques et topiques.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
The present disclosure relates to the field of pharmacy, particularly to a NLRP3 inhibitor for use in the treatment of an auto-inflammatory syndrome. The disclosure also relates to a NLRP3 inhibitor or a pharmaceutical combination comprising a NLRP3 inhibitor, or a pharmaceutically acceptable salt thereof, and at least one further therapeutic agent, for use in the treatment of an auto-inflammatory syndrome; to a method for the treatment of an auto-inflammatory syndrome that involves administering a NLRP3 inhibitor or the combination; and to the use of a NLRP3 inhibitor or the combination for the manufacture of a medicament for the treatment of an auto- inflammatory syndromes. In particular N'-((1,2,3,5,6,7-hexahydro- s-indacen-4-yl)carbamoyl)-2-(2-hydroxypropan-2-yl)thiazole-5- sulfonimidamide and enantiomers thereof are used for treating auto-inflammatory syndrome, in particular cryopyrin-associated periodic syndromes (CAPS), familial cold auto-inflammatory syndrome (FCAS), Muckle Wells syndrome (MWS), neonatal onset multisystem inflammatory disease / chronic, infantile, neurological, cutaneous and articular syndrome (NOMID/CINCA), or Familial Mediterranean Fever (FMF).
The present invention pertains to the use for treating organ injury, in particular acute organ injury, such as acute kidney injury (AKI) using CD39, human recombinant CD39 and variants thereof.
The present invention pertains to the use of miRNA technology for improving recombinant production of CD39 or variants thereof in CHO cells. The miRNA is used for knockdown of the endogenous protein CCL2 of the CHO cells which is difficult to separate from CD39 or variants thereof during purification.
This disclosure provides methods for treating a B-cell lymphoma, by administering a CD 19 CAR therapy as described herein, in combination with a BCL2 inhibitor as described herein.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to methods of identifying a subject for treatment with or treating a subject with a tricyclic AKR1C3 dependent KARS inhibitor of formula (I), or a pharmaceutically acceptable salt thereof. The methods may comprise determining in a subject sample a level of at least one of the following biomarkers: AKR1C3, NFE2L2, KEAP1, or CUL3, wherein an elevated level of the biomarker identifies the subject as being in need of treatment; or detecting in a subject sample a somatic mutation in at least one of the following genes: NFE2L2, KEAP1, or CUL3, wherein detecting the somatic mutation identifies the subject as being in need of treatment.
The present invention relates to solid phase pharmaceutical compositions of 6'-fluoro-N-(4-fluorobenzyl)-4'-oxo-3',4'-dihydro-1'H-spiro[piperidine-4,2'-quinoline]-1-carboxamide that is useful as a AKR1C3 dependent KARS inhibitor. The present invention also relates to processes for the preparation of said pharmaceutical compositions of said compound, methods of using said pharmaceutical compositions in the treatment of various diseases and disorders, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
93.
CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
(1) Providing access to an electronic exchange of medical records across a nationwide health information network; providing access to databases
(2) Educational services in the field of health equity; providing information in the field of community social events through a database; providing non-downloadable educational information, commentary and articles in the field of mental and physical health and wellness through a website; providing online electronic publications, not downloadable, in the field of medicine via the internet; providing online non-downloadable videos in the field of medicine
(3) Educational and training services in the field of multiple sclerosis; publication of information in the field of multiple sclerosis.
(4) Computer services, namely, creating an online community for registered users to participate in discussions, share recommendations, get feedback from their peers, from virtual communities and engage in social networking; hosting an online community website; hosting computer databases; hosting websites on the internet; providing temporary use of non-downloadable software for accessing databases in connection with research and development services in the fields of medicine
(5) Advisory and consultancy services for patients in the field of patient access to medical treatment services; counselling regarding the choice of medication, drug usage and information on side effects; information, advisory and consultancy services in the field of medical care and analysis services; information, advisory and consultancy services in the field of medical clinic services; information, advisory and consultancy services in the field of medical treatment services; information, advisory and consultancy services in the field of pharmacy advice services; providing information in the field of chronic health conditions via a website; providing information in the field of the prevention, screening, diagnosis and treatment of neurological disorders and diseases
(6) Providing medical information in the field of multiple sclerosis; medical services in the field of multiple sclerosis.
(7) Internet-based social networking services; providing social networking information through the use of online computer databases and online searchable databases
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and gene therapy products in the nature of injectable biologic preparations for genetic, neurological, motor neuron, or neuromuscular diseases, disorders and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials for treating spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy preparations in the nature of biological preparations containing genetic materials for sustained survival motor neuron protein expression
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques et produits de thérapie génique sous forme de préparations biologiques injectables pour les maladies, troubles et conditions génétiques, neurologiques, du motoneurone ou neuromusculaires; préparations pharmaceutiques et produits de thérapie génique sous forme de préparations biologiques contenant du matériel génétique pour le traitement de l'amyotrophie spinale, de la perte des motoneurones, de la dégénérescence musculaire, de la faiblesse musculaire et de la paralysie; préparations de thérapie génique sous forme de préparations biologiques contenant du matériel génétique pour une expression soutenue de la protéine du motoneurone de survie (SMN).
The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The Trustees of the University of Pennsylvania (USA)
Inventor
Fachin, Fabio
Cao, Lan
Greene, Michael R.
Golovina, Tatiana
Abstract
The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
The disclosure relates to a molecule that inhibits BAFF pathway, particularly an antibody or a binding fragment thereof, particularly an anti-BAFF-R antibody, e.g. ianalumab, for use in the treatment of autoimmune hemolytic anemia (AIHA), in particular, warm autoimmune hemolytic anemia (wAIHA).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligands having a glutamate-urea-lysine (GUL) moiety and a chelating agent that can comprise a radiometal.